Gastrointestinal cancer refers to malignant conditions of the gastrointestinal tract, including the esophagus, stomach, liver, biliary system, pancreas, bowels, and anus.
Tapping into an ancient evolutionary survival mechanism, cancer cells enter into a sluggish, slow-dividing state to survive the harsh environment created by chemotherapy or other targeted agents.
Recently there have been significant advances on several fronts in the ongoing war against cancer of the alimentary tract.
A phase 1 clinical trial of sotorasib (AMG 510) in patients with heavily pretreated advanced solid tumors shows encouraging anti-cancer activity, especially in lung and colorectal cancers, reports a new study led by City of Hope and other renowned comprehensive cancer centers.
A single-center observational study of more than 1,000 oncological examinations has demonstrated that positron emission tomography/magnetic resonance imaging (PET/MRI) facilitates cancer staging as well as PET/computed tomography (PET/CT) and improves lesion detectability in select cancers, potentially helping to promote fast, efficient local and whole-body staging in one step.
Dr. Ananya Malhotra speaks to News-Medical about her research into how pancreatic cancer prognosis could be improved by using artificial intelligence.
A team led by University of Saskatchewan (USask) researcher Khan Wahid has been awarded $250,000 from the federal New Frontiers in Research Fund to create a new pill-sized capsule that uses artificial intelligence (AI)-enabled sensing to diagnose gastrointestinal cancers and bleeding earlier and more precisely than is currently possible.
Months into the coronavirus pandemic, older adults are having a hard time envisioning their "new normal."
People with inoperable anal cancer treated with carboplatin-paclitaxel had fewer complications and lived longer than those who received another chemotherapy that has been more often administered.
Persistent inflammation of the pancreas (chronic pancreatitis) is a known risk factor for developing pancreatic cancer, the third-deadliest cancer in the United States.
Oncotarget Volume 11, Issue 10 reported that dysregulation of noncoding micro RNA molecules has been associated with immune cell activation in the context of Helicobacter pylori-induced gastric inflammation as well as carcinogenesis, but also with downregulation of mismatch repair genes, and may interfere with immune checkpoint proteins that lead to the overexpression of antigens on gastric tumor cells.
In a paper published online today, Dana-Farber Cancer Institute researchers provide new details about a recently discovered condition in which childhood cancer survivors develop numerous colorectal growths called polyps despite not having a hereditary susceptibility to the condition.
Inflammatory bowel disease is a category of refractory inflammatory disease, of which ulcerative colitis and Crohn's disease are the main types.
Conventional wisdom says that having just one mutated copy of the cystic fibrosis gene has no effects on a person's health--the disease occurs when both copies of the gene are mutated. But a new study from the University of Iowa suggests that may not be the case.
Proton therapy leads to significantly lower risk of side effects severe enough to lead to unplanned hospitalizations for cancer patients when compared with traditional radiation, while cure rates between the two groups are almost identical.
Artificial intelligence (AI) is being tested in clinics around the world, but is it a realistic ambition to apply sophisticated algorithms to cancer care?
A diet high in fiber and yogurt is associated with a reduced risk for lung cancer, according to a study by Vanderbilt University Medical Center researchers published in JAMA Oncology.
Research led by VHIO's Alena Gros signposts a new, less invasive approach to identify killer T lymphocytes in patients with gastrointestinal tumors with low mutational burden who are refractory to approved immune-based treatments.
A clinical trial has shown that using a combination of three drugs that target a BRAF gene mutation in patients with mCRC effectively boosts overall survival.
The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
Cancer patients who miss an urgent referral appointment for their symptoms are 12% more likely to die within 12 months of diagnosis, a major new study has found.